Intellectual Property - April 10, 2019
Additional patent protection for Oncopeptides
The US patent and trademark office has issued a notice that they intend to grant additional patents to Oncopeptides AB in the US. These patents protect, inter alia, the freeze-dried formulation. The patent protection extends to 2033. The freeze-dried preparation with melflufen is intended to be marketed at a future approval. Major key markets “We […]
Intellectual Property - April 1, 2019
Patent approval for Biovica
The Uppsala-based company receives an additional patent on the US market for their PCR-based product. The patent is a kit-patent that protects against competing companies making copies of Biovicas product. The patent complements previous patent on the US market, which protects the method for the analyzis, making the protection even stronger. The patent is valid […]
Intellectual Property - March 26, 2019
LIDDS’ technology receives US patent
The United States Patent and Trademark Office has issued a Notice of Allowance for the NanoZolid technology patent. The same patent was approved by the European Patent Office in 2018. With this new US patent, the NanoZolid technology will be protected until 2037 in both Europe and in the US. LIDDS will pursue additional patent […]
Intellectual Property - March 20, 2019
Lobsor granted US patent
Lobsor Pharmaceuticals has been granted the US patent covering a pharmaceutical composition for the treatment of neurodegenerative disorders such as Parkinson’s disease. Lobsor has earlier received market authorization by the Swedish Medical Products Agency (MPA) for their lead product, Lecigon, a new therapeutic system for symptomatic treatment of Advanced Parkinson’s disease (APD). Lecigon comprises the […]
Intellectual Property - February 7, 2019
The patent infringement lawsuit against Genmab is over
Genmab, Janssen and MorphoSys have agreed to end the patent infringement lawsuit launched by MorphoSys AG relating to DARZALEX. On January 25, 2019, the U.S. District Court of the District of Delaware ruled that all three patents that MorphoSys had asserted against Genmab and Janssen Biotech, Inc. (Janssen) are invalid. Genmab and Janssen’s allegations that […]
Intellectual Property - January 21, 2019
Targovax granted European patent
The patent protects Targovax’ mutant-RAS specific neoantigen peptides, mutant RAS specific T cells and vaccines TG01 and TG02, for the treatment of cancer in combination with chemotherapies. “We are delighted that this European patent has been granted, further strengthening Targovax’ intellectual property portfolio covering the very important mutant-RAS neoantigen and mutant-RAS specific T cells. The […]
